Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma
The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with
Read more
The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with
Read moreA drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be
Read more